Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 3
1984 1
1988 2
1989 1
1990 1
1991 2
1992 1
1993 3
1994 3
1995 3
1996 3
1997 2
1998 10
1999 3
2000 14
2001 7
2002 11
2003 9
2004 13
2005 25
2006 22
2007 21
2008 24
2009 18
2010 17
2011 22
2012 24
2013 29
2014 18
2015 38
2016 29
2017 19
2018 24
2019 18
2020 23
2021 20
2022 28
2023 25
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

499 results

Results by year

Filters applied: . Clear all
Proximity search should include two or more words. Proximity operator ignored :~0
Page 1
Management of obesity.
Bray GA, Frühbeck G, Ryan DH, Wilding JP. Bray GA, et al. Lancet. 2016 May 7;387(10031):1947-56. doi: 10.1016/S0140-6736(16)00271-3. Epub 2016 Feb 10. Lancet. 2016. PMID: 26868660 Free article. Review.
Medications approved in the USA or European Union are orlistat, naltrexone/bupropion, and liraglutide; in the USA, lorcaserin and phentermine/topiramate are also available. ...
Medications approved in the USA or European Union are orlistat, naltrexone/bupropion, and liraglutide; in the USA, lorcaserin and phe …
Obesity: Pathophysiology and Management.
Gadde KM, Martin CK, Berthoud HR, Heymsfield SB. Gadde KM, et al. J Am Coll Cardiol. 2018 Jan 2;71(1):69-84. doi: 10.1016/j.jacc.2017.11.011. J Am Coll Cardiol. 2018. PMID: 29301630 Free PMC article. Review.
Lifestyle modification is recommended as the cornerstone of obesity management, but many patients do not achieve long-lasting benefits due to difficulty with adherence as well as physiological and neurohormonal adaptation of the body in response to weight loss. Fortunately, 5 dru …
Lifestyle modification is recommended as the cornerstone of obesity management, but many patients do not achieve long-lasting benefits due t …
Treatment of Tobacco Smoking: A Review.
Rigotti NA, Kruse GR, Livingstone-Banks J, Hartmann-Boyce J. Rigotti NA, et al. JAMA. 2022 Feb 8;327(6):566-577. doi: 10.1001/jama.2022.0395. JAMA. 2022. PMID: 35133411 Review.
Both behavioral counseling and pharmacotherapy while using nicotine replacement therapy (NRT) products, varenicline, or bupropion are effective treatments when used individually, but they are most effective when combined. In a meta-analysis including 19 488 people w …
Both behavioral counseling and pharmacotherapy while using nicotine replacement therapy (NRT) products, varenicline, or bupropion …
Obesity Management in Adults: A Review.
Elmaleh-Sachs A, Schwartz JL, Bramante CT, Nicklas JM, Gudzune KA, Jay M. Elmaleh-Sachs A, et al. JAMA. 2023 Nov 28;330(20):2000-2015. doi: 10.1001/jama.2023.19897. JAMA. 2023. PMID: 38015216 Review.
Evidence-based obesity treatment includes interventions addressing 5 major categories: behavioral interventions, nutrition, physical activity, pharmacotherapy, and metabolic/bariatric procedures. Comprehensive obesity care plans combine appropriate interventions for indivi …
Evidence-based obesity treatment includes interventions addressing 5 major categories: behavioral interventions, nutrition, physical activit …
AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity.
Grunvald E, Shah R, Hernaez R, Chandar AK, Pickett-Blakely O, Teigen LM, Harindhanavudhi T, Sultan S, Singh S, Davitkov P; AGA Clinical Guidelines Committee. Grunvald E, et al. Gastroenterology. 2022 Nov;163(5):1198-1225. doi: 10.1053/j.gastro.2022.08.045. Epub 2022 Oct 20. Gastroenterology. 2022. PMID: 36273831
The panel suggested the use of semaglutide 2.4 mg, liraglutide 3.0 mg, phentermine-topiramate ER, and naltrexone-bupropion ER (based on moderate certainty evidence), and phentermine and diethylpropion (based on low certainty evidence), for long-term management of overweigh …
The panel suggested the use of semaglutide 2.4 mg, liraglutide 3.0 mg, phentermine-topiramate ER, and naltrexone-bupropion ER (based …
A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD).
Sharma A, Couture J. Sharma A, et al. Ann Pharmacother. 2014 Feb;48(2):209-25. doi: 10.1177/1060028013510699. Epub 2013 Nov 1. Ann Pharmacother. 2014. PMID: 24259638 Review.
This review, therefore, focuses on the pathophysiology, etiology, and treatment of ADHD and details the adverse effects and drug interaction profiles of the drugs used to treat it. CONCLUSIONS: Published research shows the benefit of drug therapy for ADHD in children, but …
This review, therefore, focuses on the pathophysiology, etiology, and treatment of ADHD and details the adverse effects and drug interaction …
Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
Tak YJ, Lee SY. Tak YJ, et al. Curr Obes Rep. 2021 Mar;10(1):14-30. doi: 10.1007/s13679-020-00422-w. Epub 2021 Jan 6. Curr Obes Rep. 2021. PMID: 33410104 Free PMC article. Review.
Currently, the anti-obesity medications that have been approved by the FDA for chronic weight management are orlistat, phentermine/topiramate, naltrexone/bupropion, and liraglutide. However, they are costly and may have adverse effects in some individuals. Therefore, drug …
Currently, the anti-obesity medications that have been approved by the FDA for chronic weight management are orlistat, phentermine/topiramat …
Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials.
Hayasaka Y, Purgato M, Magni LR, Ogawa Y, Takeshima N, Cipriani A, Barbui C, Leucht S, Furukawa TA. Hayasaka Y, et al. J Affect Disord. 2015 Jul 15;180:179-84. doi: 10.1016/j.jad.2015.03.021. Epub 2015 Mar 31. J Affect Disord. 2015. PMID: 25911132 Free article.
In the primary analysis, fluoxetine 40mg/day was equivalent to paroxetine dosage of 34.0mg/day, agomelatine 53.2mg/day, amitriptyline, 122.3mg/day, bupropion 348.5mg/day, clomipramine 116.1mg/day, desipramine 196.3mg/day, dothiepin 154.8mg/day, doxepin 140.1mg/day, escital …
In the primary analysis, fluoxetine 40mg/day was equivalent to paroxetine dosage of 34.0mg/day, agomelatine 53.2mg/day, amitriptyline, 122.3 …
Clinical Management of Bleeding Risk With Antidepressants.
Bixby AL, VandenBerg A, Bostwick JR. Bixby AL, et al. Ann Pharmacother. 2019 Feb;53(2):186-194. doi: 10.1177/1060028018794005. Epub 2018 Aug 6. Ann Pharmacother. 2019. PMID: 30081645 Review.
Antidepressants with low or no affinity for the serotonin transporter, such as bupropion or mirtazapine, may be appropriate alternatives for patients at risk of bleeding. Relevance to Patient Care and Clinical Practice: This review includes data regarding bleeding r …
Antidepressants with low or no affinity for the serotonin transporter, such as bupropion or mirtazapine, may be appropriate alternati …
Clinical management of psychostimulant withdrawal: review of the evidence.
Li MJ, Shoptaw SJ. Li MJ, et al. Addiction. 2023 Apr;118(4):750-762. doi: 10.1111/add.16093. Epub 2022 Dec 12. Addiction. 2023. PMID: 36401591 Free PMC article. Review.
Potential efficacy for MA withdrawal is noted for a few medications (mirtazapine, naltrexone, bupropion) and repetitive transcranial magnetic stimulation during acute (first week), early protracted (weeks 2-4) and late protracted (> 4 weeks) withdrawal phases. ...
Potential efficacy for MA withdrawal is noted for a few medications (mirtazapine, naltrexone, bupropion) and repetitive transcranial …
499 results